Clinical Trials Logo

Merkel Cell Carcinoma clinical trials

View clinical trials related to Merkel Cell Carcinoma.

Filter by:

NCT ID: NCT03583528 Recruiting - Neuroblastoma Clinical Trials

DOTATOC PET/CT for Imaging NET Patients

Start date: July 11, 2018
Phase:
Study type: Observational

Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called somatostatin receptors (SSTR). Somatostatin receptor scintigraphy and conventional imaging are used to detect NETs. This study proposes 68Gallium(68Ga)-DOTATOC positron emission tomography/computed tomography (PET/CT) is superior to current imaging techniques. The goal is to evaluate the safety and sensitivity of 68Ga-DOTATOC PET/CT at detecting NETs and other tumors with over-expression of somatostatin receptors.

NCT ID: NCT03370861 Recruiting - Melanoma Clinical Trials

How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes

MINING
Start date: November 8, 2017
Phase:
Study type: Observational

The purpose of this research study is to examine the relationship between the microbiota (microscopic organisms) in the gut and the activity of the immune system during skin cancer immunotherapy.

NCT ID: NCT03212404 Recruiting - Clinical trials for Head and Neck Cancer

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Start date: September 20, 2017
Phase: Phase 1
Study type: Interventional

CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.

NCT ID: NCT03210935 Recruiting - Clinical trials for Merkel Cell Carcinoma

French National Database of Rare Dermatological Cancers

CARADERM
Start date: November 24, 2015
Phase:
Study type: Observational

Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes. CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are : - to provide epidemiological, clinical and socio-economic characteristics of patients - to identify new clinical or epidemiological prognostic factors for these rare cancers - to evaluate the impact of various treatments on outcomes

NCT ID: NCT02479698 Recruiting - Clinical trials for Human Immunodeficiency Virus

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

Start date: July 23, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and/or JC virus.